Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy as maintenance after first-line therapy in HER2-negative advanced gastric cancer
ChiCTR2400089076Phase 2Not yet recruiting
- Sponsor
- Sichuan Mianyang 404 Hospital
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine in gastric cancer (GC) and esophagogastric junction cancer (2 arms), sponsored by Sichuan Mianyang 404 Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2400089076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089076.